Repositioning Candidate Details
| Candidate ID: | R0798 |
| Source ID: | DB05433 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | rGLP-1 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant. GLP-1 is a naturally occurring hormone produced in the intestines in response to food intake. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in congestive heart failure and diabetes mellitus type 2. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | These rGLP-1 mimetics bind to rGLP-1 receptors with similar affinity and produce biological actions identical to those of native rGLP-1 which controls blood glucose via multiple actions including stimulation of insulin secretion and inhibition of both glucagon secretion and gastric emptying. Preclinical data suggest that rGLP-1 analogs engage signaling pathways in the islet beta-cell that lead to stimulation of beta-cell replication and inhibition of beta-cell apoptosis. |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |